12/17
08:15 am
annx
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Medium
Report
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
12/16
04:05 pm
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
12/16
07:47 am
annx
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) [Yahoo! Financ
Low
Report
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) [Yahoo! Financ
12/16
07:30 am
annx
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
High
Report
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
12/5
08:10 am
annx
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting [Yahoo! Finance]
Medium
Report
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting [Yahoo! Finance]
12/5
08:00 am
annx
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
Medium
Report
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
11/15
05:15 pm
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/15
04:59 pm
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
11/15
10:27 am
annx
Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/15
08:04 am
annx
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Medium
Report
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
11/15
08:04 am
annx
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Medium
Report
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/14
08:12 am
annx
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones [Yahoo! Finance]
Medium
Report
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones [Yahoo! Finance]
11/14
08:00 am
annx
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
Medium
Report
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
11/13
04:22 pm
annx
Annexon Biosciences to Present at the Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Annexon Biosciences to Present at the Jefferies London Healthcare Conference [Yahoo! Finance]
11/13
04:05 pm
annx
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
Medium
Report
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
10/21
08:15 pm
annx
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting [Yahoo! Finance]
Low
Report
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting [Yahoo! Finance]
10/21
08:00 pm
annx
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Low
Report
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
10/21
10:17 am
annx
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely [Yahoo! Finance]
10/16
08:00 am
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
10/15
08:00 am
annx
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Low
Report
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting